Lilly's Obesity Pill Reaches 6,000 Prescriptions in Third Week After Launch

Eli Lilly's new obesity treatment pill has reached approximately 6,000 prescriptions in its third week after launch. This data indicates the rate of patient acceptance and adoption by physicians. The company notes that the oral form of the treatment, being easier to administer compared to injection-based rivals, has boosted demand. According to Reuters, Lilly's obesity pill has gained strong momentum in its initial period. Prescription numbers rose rapidly in the first weeks, approaching the 6,000 mark in the third week. This figure provides positive signals regarding the drug's potential market size. Analysts state that Lilly's success demonstrates that oral medications for obesity treatment can reach a broader patient base compared to injections. The company aims to meet demand by increasing production capacity. However, the drug's long-term effects and competitive pressures continue to be monitored. This is not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 60%

The news headline is not directly related to GOOGL, but rather focuses on Lilly's obesity pill. However, GOOGL's technical indicators point to a strong short-term uptrend: the RSI is approaching overbought territory at 66.9, the MACD is positive and above its signal line, and the price has closed above both the 20-day and 50-day moving averages. Nevertheless, the sectoral impact of the news may be indirect, and the overbought signal in the technical indicators increases the risk of a short-term correction. Therefore, rather than determining a clear direction, maintaining a neutral stance appears more appropriate.

RSI 14

66.9

MACD

4.32

24h Δ

3.67%

📊 LLY — Piyasa Yorumu

▲ up · 60%

The news indicates that Eli Lilly's obesity pill has reached 6,000 prescriptions in its third week since launch, signaling strong demand for the drug and potentially positive market reception. Technically, the RSI stands at 52.8, in neutral territory, while the MACD is positive but below the signal line. The price is below the 20-day SMA but above the 50-day SMA. In the short term, this news could generate buying interest in the stock, though the price needs to break above the 20-day SMA. Therefore, an upward move may be expected, but caution is advised.

RSI 14

52.8

MACD

4.96

24h Δ

0.91%

Canlı Grafikler